Cochrane · systematic review · CD011532
Terlipressin versus other vasoactive drugs for hepatorenal syndrome
Israelsen, M, Krag, A, Allegretti, AS, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 4 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Terlipressin compared to other vasoactive drugs for hepatorenal syndrome
Population: people with cirrhosis and hepatorenal syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality (All‐cause) Terlipressin vs other vasoactive drugs | RR 0.96 [0.88, 1.06] | 474 participants | Very low Downgraded: risk of bias |
Hepatorenal syndrome (Number of participants who did not achieve reversal of hepatorenal syndrome) Terlipressin vs other vasoactive drugs | RR 0.79 [0.63, 0.99] | 394 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Serious adverse events Terlipressin vs other vasoactive drugs | RR 0.96 [0.88, 1.06] | 474 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Non‐serious adverse events: diarrhoea or abdominal pain, or both Terlipressin vs other vasoactive drugs | RR 3.5 [1.19, 10.27] | 221 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |